Lyell Immunopharma, Inc. Revenue from Related Parties
Lyell Immunopharma, Inc. (LYEL) reported Revenue from Related Parties of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-04.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2023-05-04
- Lyell Immunopharma, Inc. revenue from related parties for the quarter ending 2023-03-31 was $0.00.
- Lyell Immunopharma, Inc. revenue from related parties for the quarter ending 2022-12-31 was $48.35M, a 1619.56% increase year-over-year.
- Lyell Immunopharma, Inc. revenue from related parties for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. revenue from related parties for the quarter ending 2021-12-31 was $2.81M.
- Lyell Immunopharma, Inc. revenue from related parties for fiscal 2022 was $84.65M, a 705.53% increase from fiscal 2021.
- Lyell Immunopharma, Inc. revenue from related parties for fiscal 2021 was $10.51M, a 35.50% increase from fiscal 2020.
- Lyell Immunopharma, Inc. revenue from related parties for fiscal 2020 was $7.76M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $48.35M derived: sum of 2 quarters · filed 2023-05-04 | $48.35M derived: sum of 3 quarters · filed 2023-05-04 | |
| 2022-12-31 | $48.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $48.35M derived: sum of 2 quarters · filed 2023-02-28 | $84.65M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | $36.30M 10-Q · filed 2022-11-08 | ||
| 2021-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.45M derived: sum of 2 quarters · filed 2023-02-28 | $10.51M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $2.64M 10-Q · filed 2022-11-08 | $7.70M 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $7.76M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |